Report from the Generics Bulletin on Alberta becoming the third province in Canada to apply its biosimilar switch policy to Humira adalimumab, the #2 top-selling biologic drug in Canada.
Report from the Generics Bulletin on Alberta becoming the third province in Canada to apply its biosimilar switch policy to Humira adalimumab, the #2 top-selling biologic drug in Canada.